We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
In the latest close session, Adma Biologics (ADMA - Free Report) was up +2.39% at $17.13. This change outpaced the S&P 500's 0.14% gain on the day. Elsewhere, the Dow lost 0.04%, while the tech-heavy Nasdaq added 0.38%.
Shares of the infectious disease drug developer have depreciated by 5.69% over the course of the past month, underperforming the Medical sector's loss of 1.94%, and the S&P 500's gain of 5.35%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure. The company is expected to report EPS of $0.14, up 7.69% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $121.1 million, up 12.98% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.61 per share and revenue of $505.8 million, which would represent changes of +24.49% and +18.61%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 8.27% lower. Adma Biologics is currently a Zacks Rank #4 (Sell).
Looking at valuation, Adma Biologics is presently trading at a Forward P/E ratio of 27.43. This signifies a premium in comparison to the average Forward P/E of 17.79 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 86, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
In the latest close session, Adma Biologics (ADMA - Free Report) was up +2.39% at $17.13. This change outpaced the S&P 500's 0.14% gain on the day. Elsewhere, the Dow lost 0.04%, while the tech-heavy Nasdaq added 0.38%.
Shares of the infectious disease drug developer have depreciated by 5.69% over the course of the past month, underperforming the Medical sector's loss of 1.94%, and the S&P 500's gain of 5.35%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure. The company is expected to report EPS of $0.14, up 7.69% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $121.1 million, up 12.98% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.61 per share and revenue of $505.8 million, which would represent changes of +24.49% and +18.61%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 8.27% lower. Adma Biologics is currently a Zacks Rank #4 (Sell).
Looking at valuation, Adma Biologics is presently trading at a Forward P/E ratio of 27.43. This signifies a premium in comparison to the average Forward P/E of 17.79 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 86, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.